Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for ... Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. 詳細を表示
WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s...
MB-108 (HSV-1 oncolytic virus) is active and well tolerated in patients with recurrent glioblastoma in ongoing Phase 1 clinical trial Preclinical data support a novel combination of MB-108 (HSV-1...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0204 | -10.2 | 0.2 | 0.2044 | 0.1539 | 827397 | 0.17561327 | CS |
4 | -0.0234 | -11.5270935961 | 0.203 | 0.2167 | 0.1539 | 640146 | 0.18817153 | CS |
12 | -0.0699 | -28.0160320641 | 0.2495 | 0.3701 | 0.1539 | 1909457 | 0.27344508 | CS |
26 | -0.3904 | -68.4912280702 | 0.57 | 0.8588 | 0.1539 | 3077389 | 0.41715506 | CS |
52 | -1.1904 | -86.8905109489 | 1.37 | 1.53 | 0.1281 | 8012398 | 0.65037867 | CS |
156 | -27.1204 | -99.3421245421 | 27.3 | 29.55 | 0.1281 | 2984394 | 1.82459664 | CS |
260 | -49.7704 | -99.6404404404 | 49.95 | 78.3 | 0.1281 | 2379566 | 14.08025168 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約